Hemodynamic Implications of Transcatheter Tricuspid Valve Repair in HFpEF Patients

NCT ID: NCT04782908

Last Updated: 2021-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate the pathophysiological implications of transcatheter tricuspid valve edge-to-edge repair in patient with heart failure and preserved ejection fraction and severe tricuspid regurgitation. Changes in right- and left-ventricular function as well as the interventricular dependence will be analysed on a multimodal basis including pressure-volume loop analysis and cardiac magnetic resonance imaging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure Tricuspid Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Patients undergoing transcatheter tricuspid valve edge-to-edge repair will undergo multimodal cardiovascular diagnostics before and after tricuspid valve repair including pressure volume loop analysis and cardiac magnetic resonance imaging
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Outcome assessors will be blinded whether they are analysing pre or post transcatheter tricuspid valve edge-to-edge repair data.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcatheter tricuspid valve edge-to-edge repair

Patients will undergo transcatheter tricuspid valve edge-to-edge repair (TTVR) and hemodynamic characteristics will be analysed on a multimodal approach using cardiac magnetic resonance imaging and pressure volume loop analysis before and after TTVR.

Group Type EXPERIMENTAL

Transcatheter tricuspid valve edge-to-edge repair

Intervention Type DEVICE

Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter tricuspid valve edge-to-edge repair

Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe tricuspid regurgitation with need for interventional treatment approach as decided by an interdisciplinary heart team.
* Signs and symptoms of left-sided heart failure.
* Left-ventricular ejection fraction ≥50%
* Invasive evidence of elevated left-ventricular fillings pressures (pulmonary capillary wedge pressure \[PCWP\] or left-ventricular end-diastolic pressure ≥15 mmHg)

Exclusion Criteria

* Concomitant relevant mitral valve regurgitation with need for concomitant interventional treatment
* Moderate aortic stenosis.
* Pregnancy
* Contraindication to perform cardiac magnetic resonance imaging.
* Conditions rendering patient unable to give informed consent to the study protocol.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heart Center Leipzig - University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Philipp Lurz

Professor, Managing Senior Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Centre at University Leipzig

Leipzig, Saxony, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Karl-Patrik Kresoja, MD

Role: CONTACT

0341865252596

Philipp Lurz, MD, PhD

Role: CONTACT

0341865252529

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Karl-Patrik Kresoja, MD

Role: primary

0341 865 252596

Philipp Lurz, MD, PhD

Role: backup

0341 865 252529

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HERACLES-HFpEF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Guided Placement of CRT-Leads
NCT00764075 COMPLETED NA